National projects managed by Innovation Acta


innova

INNOVA

Progetto – PNC- E3-2022-23683266 – DIAGNOSTICA AVANZATA (HLS-DA), finanziato dal Ministero della Salute nell’ambito del Piano Nazionale Complementare Ecosistema Innovativo della Salute.

Starting Date: 2 January 2023
Project number: PNC- E3-2022-23683266
MoH Funding: € 40,000,000

 

Currently ongoing grants Horizon Europe and Horizon 2020


IHI/IMI

immutol

LIVERAIM
101132901-HORIZON-JU-IHI-2022-03-single-stage

A biomarker-based platform for early diagnosis of chronic liver disease to enable personalised therapy

Starting Date: 1 March 2024
Grant Agreement: 101132901
Project Cost: € 24,789,953.89
EC Funding: € 13,854,592.75

immutol

GUIDE.MRD
Project 101080562101112066- HORIZON-JU-IHI-2022-01-03

GUIding multi-moDal thErapies against MRD by liquid biopsies - GUIDE.MRD

Starting Date: 1 May 2023
Grant Agreement: 101112066
Project Cost: € 34.452.565
EC Funding: € 17.660.955

necessity

NECESSITY
IMI Grant

New Clinical Endpoints in primary Sjögren’s Syndrome: an Interventional Trial based on stratifying patients

Starting Date: 1 January 2019
Grant Agreement: 806975
Project Cost: € 15.485.964,84
EU Contribution: € 8.200.000,00

RIA-MISSION

necessity

THRIVE
Project: 101136622 -HORIZON-MISS-2023-CANCER-01

Tumour-host interactions in liver cancer of Childhood and adults

Starting date: 1 December 2023
Grant Agreement: 101136622
Project cost: € 10.396.703
EC funding: € 10.396.703

RIA-HEALTH

immutol

IMMUTOL
Project 101080562- HORIZON-HLTH-2022-DISEASE-06-two-stage

Advanced Antigen-Specific Dendritic Cell-Based Therapy to Re-establish Tolerance in Immune-Mediated Diseases

Starting Date: 1 May 2023
Grant Agreement: 101080562
Project Cost: € 5.999.340

proto

PROTO
Project 101095635- HORIZON-HLTH-2022-STAYHLTH-02-01

Advanced PeRsOnalized Therapies for Osteoarthritis –Tackling inflammation to improve patient outcomes

Starting Date: 1 January 2023
Grant Agreement: 101095635
Project Cost: € 7.447.875

genetiga

geneTIGA
Project 101057438 - HORIZON-HLTH-2021-TOOL-06

Gene-edited T cells combating IgA Nephropathy

Starting Date: 1 July 2022
Grant Agreement: 101057438
Project Cost: € 5.736.859

reshape

ReSHAPE
RIA BHC 09-2018

Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches - from Advanced Technology Developments to First-in-Human Trials

Starting Date: 1 January 2019
Grant Agreement: 825392
Budget: € 13.137.396,25

liverscreen

LIVERSCREEN
RIA BHC 30-2019

Screening for liver fibrosis - population-based study across European countries

Starting Date: 1 January 2020
Grant Agreement: 847989

hdm-fun

HDM-FUN
RIA BHC14-2019

Host directed medicine in invasive fungal infection

Starting Date: 1 January 2020
Grant Agreement: 847507

EIC Pathfinder

b-specific

B-SPECIFIC
Project 101115159 - HORIZON-EIC-2022-PATHFINDERCHALLENGES-01

B-cell related gene and protein markers with prognostic and therapeutic value for CVD

Starting Date: 1 October 2023
Grant Agreement: 101115159
Project Cost: € 4.006.599,85

t-fitness

T-FITNESS
Project 101070740 - HORIZON-EIC-2021-PATHFINDERCHALLENGES-01

Fine-Tuning T Cell Networks of Exhaustion by Synthetic Sensors

Starting Date: 1 September 2022
Grant Agreement: 101070740
Project Cost: € 3.789.472

restore

TwistedNano
Project 101046424 - HORIZON-EIC-2021-PATHFINDEROPEN-01

Twisted nanophotonic technology for integrated chiroptical sensing of drugs on a chip

Starting Date: 1 April 2022
Grant Agreement: 101046424
Project Cost: € 3.197.925

MSCA DN and ITN

restore

Glyco-N
Project: 101119499 - HORIZON-MSCA-2022-DN-01

GLYCOprotein N-glycosylation from non-life to eukaryotes: a Doctoral Network to expand the knowledge on a ubiquitous posttranslational modification of proteins

Starting Date: 1 February 2024
Grant Agreement: 101119499
Project Cost: € 2.677.118,4
EC funding: € 2.677.118,4

restore

ECO2WINE
Project: HORIZON-MSCA-2022-DN-01-01 (topic)

Natural microbial interactions in winemaking-associated ecosystems as a tool to foster wine innovation

Starting Date: 1 December 2023
Grant Agreement: 101119480
Project Cost: € 2.440.396,80
EC funding: € 2.440.396,80

topgut

TOPGUT
Project MSCA-DN

Training for Organoids modelling Physiology and Pathology in the human gastrointestinal tract

Starting Date: 1 November 2023
Grant Agreement: 101119911
Budget: € 2.718.489,60

extra

EXTRA
Project MSCA-DN

Innovative Applications of Extracorporeal Photopheresis in Solid Organ Transplantation

Starting Date: 1 September 2023
Grant Agreement: 101119855
Budget: € 2.613.103,20

tolerate

TREAD
Project: 101072699- HORIZON-MSCA-2021-DN-01

daTa and pRocesses in sEismic hAzarD

Starting Date: 1 January 2023
Grant Agreement: 101072699
Budget: € 2.664.388,80
EC funding: € 2.664.388,80

tolerate

TOLERATE
MSCA-DN

An integrated approach to restore tolerance in autoimmune disease

Starting Date: 1 October 2022
Grant Agreement: 101072729
Budget: € 2.109.650,40

instruct

INsTRuCT
MSCA-ITN (ETN)

INnovative Training in Myeloid Regulatory Cell Therapy

Starting Date: 1 January 2020
Grant Agreement: 860003
Budget: € 4.021.026,84

educ8

EDUC8
MSCA-ITN (ETN)

Early Stage Researchers EDUCational Program on Factor VIII Immunogenicity

Starting Date: 1 April 2020
Grant Agreement: 859974

 

Closed H2020 grants


restore

RESTORE
CSA - Large Scale Research Initiative

RESTORE Health by Advanced Therapies (Advanced Therapy Medicinal Products and Biologized Medical Devices) – ALL for Advanced Therapies – with Passion – For Patients’

Starting Date: 1 March 2019
Grant Agreement: 820292
Project Cost: € 1.000.000
EU Contribution: € 1.000.000

hipgen

HIPGEN
RIA - Research and Innovation action

Placenta-expanded adherent stromal cells (plx-pad) as an innovative therapy for improving recovery and survival following hip fracture arthroplasty - HIPGEN, a multicenter phase III trial

Starting Date: 1 January 2018
Grant Agreement: 779293

pace

PACE
RIA - Research and Innovation action

A multicenter phase III study using HLA-unmatched allogeneic placenta-derived stromal cells (PLX-PAD) for the treatment of severe critical limb ischemia accompanied by mechanistic studies

Starting Date: 1 January 2017
Grant Agreement: 733006

liverhope

LIVERHOPE
RIA - Research and Innovation action

Simvastatin and Rifaximin as new therapy for patients with decompensated cirrhosis

Starting Date: 1 January 2017
Grant Agreement: 731875

integrata

INTEGRATA
MSCA-ITN (ETN)

Integrating chemical and biological approaches to target NAD production and signaling in cancer

Starting Date: 1 November 2018
Grant Agreement: 813284
Budget: € 3.738.573,00

   


Innovation Acta S.r.l. | Via delle Province, 1 - 53100 Siena - Italy | VAT number: 13201341008

© 2020 Innovation Acta - All rights reserved

PRIVACY

Innovation Acta S.r.l.
VAT number: 13201341008

+39 0577 1652729
  +39 366 3746125

  info@innovationacta.eu
  acta_srl@pec.it

Registered office and operational headquarter:
Via delle Province, 1 - 53100 Siena - Italy


Branch office:
Via D.A. Azuni, 9 - 00196 Roma - Italy